《Evans综合征诊断和治疗中国专家共识(2024年版)》解读  

Interpretation of Chinese expert consensus on the diagnosis and treatment of Evans syndrome(2024)

作　　者：张连生[1] 刘玉梅[2] 王化泉[2] ZHANG Liansheng;LIU Yumei;WANG Huaquan(Department of Hematology,Lanzhou University Second Hospital,Lanzhou,730030,China;Department of Hematology,Tianjin Medical University General Hospital)

机构地区：[1]兰州大学第二医院血液科,兰州730030 [2]天津医科大学总医院血液科

出　　处：《临床血液学杂志》2024年第11期762-765,共4页Journal of Clinical Hematology

摘　　要：Evans综合征(Evans syndrome,ES)是一种罕见的自身免疫性疾病,其特点是临床病情严重,复发率高,常见感染和血栓性并发症,死亡率高。ES的治疗具有高度异质性,目前尚无前瞻性随机对照试验且缺乏大型回顾性研究证据,仅有少数病例报告。中华医学会血液学分会红细胞疾病(贫血)学组参考国内外最新ES相关文献制定了《Evans综合征诊断和治疗中国专家共识(2024年版)》。为更好地指导临床实践,文章拟对该共识的诊断和治疗部分进行解读。Evans syndrome(ES)is a rare autoimmune disease characterized by a severe clinical course,high recurrence rate,frequent complications such as thrombosis and infection,and high mortality.The management of ES is highly heterogeneous.The current literature on ES is limited to a scarcity of prospective randomized controlled trials or large retrospective studies,with only a few case reports.The Red Blood Cell Diseases(Anemia)Group under the Chinese Society of Hematology within the Chinese Medical Association has developed the Chinese expert consensus on the diagnosis and treatment of Evans syndrome(2024),based on the latest literature pertaining to ES.To provide better guidance for clinical practice,this article aims to interpret the consensus regarding diagnosis and treatment.

关 键 词：EVANS综合征 诊断 治疗 

分 类 号：R55[医药卫生—血液循环系统疾病]